Delving into the Latest Updates on Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	2

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

PARP7(TCDD-inducible poly [ADP-ribose] polymerase)	1
PRKDC(DNA-dependent protein kinase)	1

To evaluate the safety and tolerability of BY101298 combined with radiotherapy in patients with malignant solid tumors; to determine the recommended Phase II dose of BY101298 combined with radiotherapy in patients with malignant solid tumors; to evaluate the preliminary efficacy of BY101298 combined with radiotherapy in patients with malignant solid tumors;

Start Date19 Jul 2024

Sponsor / Collaborator

Chengdu Baiyu Pharmaceutical Co. Ltd.

[+1]

CTR20240141 / RecruitingPhase 1

一项评估BY101921单药/联合aPD-1单抗在晚期恶性实体瘤患者中的安全性、耐受性、药代动力学特征及初步疗效的多中心、开放I期临床研究

[Translation] A multicenter, open-label Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BY101921 alone or in combination with aPD-1 monoclonal antibody in patients with advanced malignant solid tumors

主要目的： 1）评价BY101921在晚期实体瘤患者中的安全性、耐受性 2）确定BY101921的最大耐受剂量（MTD）次要目的： 1）评价BY101921在晚期实体瘤患者中的药代动力学（PK）特征 2）初步评估BY101921在晚期实体瘤患者中的有效性探索性目的： 1）评估BY101921在晚期恶性实体瘤患者血浆中的代谢物谱 2）评估BY101921在晚期恶性实体瘤患者中的预测性生物标志物与有效性的关系

[Translation]

Primary objectives: 1) Evaluate the safety and tolerability of BY101921 in patients with advanced solid tumors 2) Determine the maximum tolerated dose (MTD) of BY101921 Secondary objectives: 1) Evaluate the pharmacokinetic (PK) characteristics of BY101921 in patients with advanced solid tumors 2) Preliminary evaluation of the effectiveness of BY101921 in patients with advanced solid tumors Exploratory objectives: 1) Evaluate the metabolite profile of BY101921 in plasma of patients with advanced malignant solid tumors 2) Evaluate the relationship between predictive biomarkers and effectiveness of BY101921 in patients with advanced malignant solid tumors

Start Date11 Mar 2024

Sponsor / Collaborator

Chengdu Baiyu Pharmaceutical Co. Ltd.

[+1]

100 Clinical Results associated with Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Chengdu Baiyu Jingelai Pharmaceutical Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Phase 2 Clinical

Login to view more data